Compare NTRA & PSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | PSA |
|---|---|---|
| Founded | 2003 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7B | 55.2B |
| IPO Year | 2015 | 2007 |
| Metric | NTRA | PSA |
|---|---|---|
| Price | $378.07 | $334.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 23 | 22 |
| Target Price | ★ $416.39 | $330.50 |
| AVG Volume (30 Days) | ★ 1.4M | 856.2K |
| Earning Date | 11-05-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 3.69% |
| EPS Growth | ★ 0.65 | N/A |
| EPS | N/A | ★ 6.92 |
| Revenue | $210,939,000.00 | ★ $4,824,113,000.00 |
| Revenue This Year | $26.22 | $5.81 |
| Revenue Next Year | $20.96 | $7.92 |
| P/E Ratio | ★ N/A | $46.93 |
| Revenue Growth | N/A | ★ 2.74 |
| 52 Week Low | $181.00 | $256.54 |
| 52 Week High | $437.41 | $335.55 |
| Indicator | NTRA | PSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 76.51 |
| Support Level | $187.64 | $308.79 |
| Resistance Level | $437.41 | N/A |
| Average True Range (ATR) | 19.55 | 6.44 |
| MACD | -2.75 | 3.95 |
| Stochastic Oscillator | 5.74 | 97.97 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Public Storage is the largest owner of self-storage facilities in the US, with more than 3,500 self-storage facilities in 40 states and approximately 259 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.